Techdow Pharmaceutical

Shenzhen Techdow Pharmaceutical Co., Ltd. was established in June 2004 and is located in the Shenzhen High-Tech Industrial Park, which is designated by China's Ministry of Science and Technology as a "High-Tech Park for Construction." After more than 10 years of accumulation and innovation, Techdow Pharmaceutical has developed into a large low-molecular-weight heparin pharmaceutical enterprise integrating drug research and development, production, and sales. Adhering to the values of "Science, Evidence, Diligence, Harmony," the company has strong scientific research capabilities and industrialization capabilities. Its products are exported to global markets and it has established and maintained long-term stable cooperative relationships with well-known pharmaceutical companies and customers in more than 50 countries. Techdow Pharmaceutical is China's largest low-molecular-weight heparin API production base and exporter. With strong scientific research capabilities, leading technology, a reliable quality assurance system, and excellent industrialization capabilities, its API products (enoxaparin sodium API, etc.) have earned outstanding international authoritative certifications. The company has successively passed audits by more than 20 countries, including the U.S. FDA, EU EMA, China FDA, Australia TGA, Brazil ANVISA, and Colombia INVIMA. In the U.S. FDA's GMP certification of its API workshop, it even achieved zero deficiencies twice in a row. As a company focused on developing heparin and low-molecular-weight heparin preparation business, Techdow Pharmaceutical has now become China's largest exporter of low-molecular-weight heparin preparations: in 2014, heparin sodium preparations were approved by the U.S. FDA, becoming China's first heparin preparation product to enter the U.S. market; in 2016, enoxaparin sodium preparations obtained EU EMA approval and entered the EU market as the first generic, becoming China's first biosimilar approved in the EU, thus establishing the company's leading position in the global low-molecular-weight heparin pharmaceutical field; in 2016, products were launched in Poland, and European subsidiaries were established in the UK, Germany, and other countries; in 2017, they were launched and sold in Germany, the UK, and Italy. Based on sales channel construction and development, the company continuously expanded its market share with unique product advantages, and both sales and market share increased continuously. With the company's efficient large-scale R&D structure, Techdow Pharmaceutical has become a cradle of high-quality drugs, and through excellent products and services, it fulfills its social responsibilities to customers, employees, investors, and the government, becoming a respected global pharmaceutical enterprise and making greater contributions to human health.